Check for updates

OPEN ACCESS

EDITED BY Jacob Raber, Oregon Health and Science University, United States

REVIEWED BY Li Zhang, Brown University, United States

*CORRESPONDENCE Shivon A. Robinson, i sar1@williams.edu

RECEIVED 26 June 2024 ACCEPTED 14 August 2024 PUBLISHED 29 August 2024

CITATION

Han C, Manners MT and Robinson SA (2024) Sex differences in opioid response: a role for the gut microbiome? *Front. Pharmacol.* 15:1455416. doi: 10.3389/fphar.2024.1455416

COPYRIGHT

© 2024 Han, Manners and Robinson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Sex differences in opioid response: a role for the gut microbiome?

Caitlin Han¹, Melissa T. Manners² and Shivon A. Robinson^{1*}

¹Department of Psychology, Williams College, Williamstown, MA, United States, ²Department of Biological and Biomedical Sciences, Rowan University, Glassboro, NJ, United States

Opioid drugs have been long known to induce different responses in males compared to females, however, the molecular mechanisms underlying these effects are yet to be fully characterized. Recent studies have established a link between the gut microbiome and behavioral responses to opioids. Chronic opioid use is associated with gut dysbiosis, or microbiome disruptions, which is thought to contribute to altered opioid analgesia and reward processing. Gut microbiome composition and functioning have also been demonstrated to be influenced by sex hormones. Despite this, there is currently very little work investigating whether sex differences in the gut microbiome mediate sexdependent responses to opioids, highlighting a critical gap in the literature. Here, we briefly review the supporting evidence implicating a potential role for the gut microbiome in regulating sexually dimorphic opioid response and identify areas for future research.

KEYWORDS

opioids, microbiome, sex differences, estrogen, behavior

Introduction

The opioid epidemic is a growing public health crisis in the United States. In 2022, over 80,000 people died from an opioid-related overdose (CDC, 2024). Opioids are powerful painkillers, and while they pose the risk of potential negative side effects, such as dependence, hyperalgesia, and respiratory depression (Higgins et al., 2019; Algera et al., 2021), many people rely on these drugs as a form of pain management. Over 80% of patients who undergo low-risk surgery receive opioids for postoperative pain management and more than 60% of patients who receive postoperative opioid therapy become chronic opioid users following treatment (Sun et al., 2016; Hah et al., 2017). Furthermore, an estimated 5–8 million Americans with chronic pain use opioids for long-term care (Reuben et al., 2015). On average, 8%–12% of patients using opioids to treat chronic pain develop opioid use disorder (OUD), which is characterized by uncontrollable cravings and hazardous patterns of drug use that interfere with daily functioning (Vowles et al., 2015; Pergolizzi et al., 2020).

Sex differences have been demonstrated in opioid-induced antinociception, reward, tolerance, withdrawal, and hyperalgesia (Bodnar and Kest, 2010). While the neurobiological processes underlying sex-specific opioid effects are yet to be fully characterized, some proposed mechanisms include differences in opioid metabolism, ligand-receptor dynamics, endocrine signaling, and neuroimmune activation, in addition to sex-gene interactions (Bodnar and Kest, 2010; Fullerton et al., 2018; Averitt et al., 2019). A much less explored variable is the gut microbiome, a network of bacteria and other microorganisms that colonize the gastrointestinal (GI) tract. Despite their localization in the GI tract, gut

microbiota can have widespread effects on the functioning of various systems within the body. Of great relevance for opioid signaling is the gut-brain axis, which mediates bidirectional communication between the gut and the central nervous system in part through gut-derived neuroactive metabolites and neurotransmitters (Cryan et al., 2019). For example, short-chain fatty acids (SCFAs), the main metabolite produced by microbes in the gut, are implicated in brain processes that contribute to neuroimmune functioning, stress response, and emotional affect (Silva et al., 2020). A growing body of literature implicates the role of sex hormones in modulating microbiome composition and function (Yoon and Kim, 2021). Sex differences in the gut microbiome have also been described in several gastrointestinal (Kim, 2022), autoimmune (Rizzetto et al., 2018), cardiovascular (Razavi et al., 2019), and neuropsychiatric disorders (Shobeiri et al., 2022).

Opioids produce their analgesic and mood-altering effects via interactions with the endogenous opioid system, which includes mu (MOR), kappa (KOR), and delta receptors (DOR) and their respective neuropeptide ligands, which are widely expressed throughout the central and peripheral nervous systems (Schepper et al., 2004; Emery and Akil, 2020). Opioid receptors are also present in the enteric nervous system, a division of the peripheral nervous system composed of sensory and motor neurons that regulate gut functioning (Wood and Galligan, 2004). Chronic opioid use impairs gastric motility, intestinal permeability, and bowel function, which in turn can disrupt gut microbiome homeostasis (Kurz and Sessler, 2003; Wang and Roy, 2017; Rueda-Ruzafa et al., 2020). Opioidindued gut dysbiosis, or dysregulation of the gut microbiome, is thought to mediate changes in behavioral response to opioids over time and may contribute to the development of substance use disorders (Meckel and Kiraly, 2019; Angoa-Pérez and Kuhn, 2021). However, whether sex differences in the microbiome impact these processes is unclear. Elucidating the neurobehavioral effects of opioids in the context of the gut microbiome, and how these mechanisms may be differentially affected by sex, is important for predicting opioid response and identifying risk factors. In this review, we discuss recent findings from the literature investigating sex differences in opioid response, sex differences in the gut microbiome, and the role of the microbiome in opioid response to highlight the need for further research to understand the relationship between sex-specific gut microbiome activity and sex differences in opioid response.

Sex differences in response to opioids

Opioids are well-known to induce divergent effects in males versus females. Men are diagnosed with OUD at a higher rate (Wilson et al., 2020) and are more likely to overdose on opioids compared to women (Butelman et al., 2023), whereas women report less pain relief following opioid treatment (Cepeda and Carr, 2003; Aubrun et al., 2005; LeResche et al., 2015) and experience more pronounced adverse side effects, such as nausea and vomiting (Fillingim et al., 2005). In rodent models, males generally exhibit more potent antinociceptive responses to opioids compared to females (Craft, 2003) while females appear to be more sensitive to the reinforcing effects of opioids (Craft, 2008; Karami and Zarrindast, 2008; Fulenwider et al., 2020; Phillips et al., 2020). However, it is important to note that these observations may depend on the specific opioid, dose, and duration of treatment implemented.

The natural fluctuation of gonadal hormones during the female reproductive cycle likely contributes to differences in opioid response in males versus females (Fillingim and Ness, 2000). The human reproductive cycle, known as the menstrual cycle, lasts for 28 days on average (Reed and Carr, 2015) and is commonly divided into the menstrual, follicular, ovulatory, luteal, and pre-menstrual phases (Joyce et al., 2021). Estrogen levels increase during the follicular phase and peak prior to ovulation while progesterone levels peak during the luteal phase. During menopause, ovarian estrogen production decreases significantly (Al-Azzawi and Palacios, 2009). Very few studies have directly investigated opioid response in pre-menopausal versus post-menopausal women, however, sex differences in opioid analgesia are notably diminished in elderly patients (Aubrun et al., 2005; LeResche et al., 2015).

The murine estrous cycle is analogous to the human menstrual cycle and begins 4–6 weeks after birth (Ajayi and Akhigbe, 2020). The cycle consists of four phases–proestrus, estrus, metestrus, and diestrus–and lasts approximately 4–5 days. The proestrus phase corresponds with elevated estrogen levels, whereas the metestrus and diestrus phases are associated with elevated progesterone levels (Goldman et al., 2007; Ajayi and Akhigbe, 2020).

In normally cycling female rats, morphine's analgesic effects are most potent during the proestrus phase (Stoffel et al., 2003; Terner et al., 2005). In contrast, heroin self-administration is lowest during the proestrus phase (Lacy et al., 2016). However, some studies have found periods of elevated estradiol levels to be associated with enhanced MOR-dependent synaptic plasticity (Harte-Hargrove et al., 2015) and increased demand for remifentanil self-administration using a threshold procedure (Lacy et al., 2020). Daily treatment with estradiol increases heroin self-administration in ovariectomized animals (Roth et al., 2002), though, this effect appears to be dose-dependent since higher doses of estradiol reduce heroin self-administration in both intact (Sharp et al., 2021) and ovariectomized females (Smith et al., 2021). When tested for morphine conditioned place preference (CPP), ovariectomized females exhibit less drugseeking behavior compared to intact animals (Mirbaha et al., 2009).

Gonadectomy experiments have also revealed a causal effect of sex hormones on pain processing. Gonad removal decreases opioid analgesia in males and increases analgesia in females (Terner et al., 2002; Stoffel et al., 2003), suggesting that testosterone promotes opioid antinociception whereas estradiol has the opposite effect (Xu et al., 2024). Indeed, estradiol treatment in ovariectomized females reduces the effectiveness of opioids in attenuating pain (Ji et al., 2007). Furthermore, estradiol upregulates the expression of UDPglucuronosyltransferase 1A9 (UGT1A9) (Cho et al., 2016), one of several enzymes within the UGT family that metabolizes opioids (Gregori et al., 2012). Following morphine exposure, females exhibit higher plasma levels of morphine-3-glucuronide (M3G), a metabolite that opposes the analgesic effects of morphine (Baker and Ratka, 2002; Doyle and Murphy, 2018). Altogether, these findings provide strong support for the modulation of opioid signaling by sex hormones.

Further research is needed to elucidate the relationship between the menstrual cycle and opioid response in humans. Some studies indicate that women experience greater opioid analgesia during the follicular phase compared to the luteal phase (Ribeiro-Dasilva et al., 2011; Miniksar et al., 2023), whereas others report no differences in opioid pain relief across the menstrual cycle (Sener et al., 2005; Ahmed et al., 2012). While there is evidence suggesting that ovarian hormones influence addictive behaviors in the context of alcohol and nicotine use (Joyce et al., 2021; Towers et al., 2022), there is a striking lack of studies investigating interactions between the menstrual cycle and opioid use.

Sex differences in the gut microbiome

The human gut contains over 10¹⁴ bacteria which are primarily represented by six phyla: *Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria*, and *Verrucomicrobia* (Arumugam et al., 2011). Among the diverse range of bacterial species that inhabit the gut, some are considered "good" bacteria, or health-promoting, while others are pathogenic (Zaky et al., 2021), For example, *Lactobacillus* and *Bifidobacterium* bacterial strains are generally considered to be beneficial (Reid, 1999; Cronin et al., 2011), and are used in treating several gut and bowel-related diseases (O'Callaghan and Sinderen, 2016; Li et al., 2023). In contrast, alterations in the ratio of abundance of *Firmicutes* to *Bacteroidetes* are associated with obesity and inflammatory bowel disease (Stojanov et al., 2020).

The colonization of the gut begins immediately following birth via exposure to maternal vaginal and fecal microbiota along with microbes introduced from the environment (Vaishampayan et al., 2010). Although there are some heritable components of the gut microbiome (Hall et al., 2017), nongenetic factors such as birth method (i.e., vaginal versus caesarean section), diet (i.e., formula vs. breastmilk), medication, and other early life experiences can modulate the development of the gut microbiome (Turroni et al., 2018; Hantsoo and Zemel, 2021). The gut microbiome typically stabilizes during toddlerhood; however, it can continue to be influenced by various environmental and psychosocial factors throughout the lifespan (Yatsunenko et al., 2012; Badal et al., 2020).

The composition of the gut microbiome varies depending on sex. A sex-specific examination of the gut microbiota of 1,135 individuals demonstrated that women have increased microbial diversity compared to men (Sinha et al., 2019). The relative abundance of SCFA-producing bacterial genera, such as *Prevotella*, is higher in pre-menopausal women compared to men, while post-menopausal women have a similar level of abundance to men (Santos-Marcos et al., 2018). The analysis of 89 different inbred mice strains revealed that the commonly used C57BL/6J strain has one of the most prominent sexually dimorphic microbiomes, with females harboring a higher abundance of *Coprococcus* and *Bacteroides* compared to males (Org et al., 2016).

Sex differences in the microbiome are mediated in part by gonadal hormones. Men and women with high serum levels of testosterone and estradiol, respectively, exhibit greater diversity in gut microbiota compared to those with low concentrations (Shin et al., 2019). In rodent models, gonadal hormones produced during puberty make the male gut microbiome less diverse than females (Yurkovetskiy et al., 2013). Notably, male mice castrated before puberty show a similar level of species diversity to that of intact females. Testosterone administration also has a protective effect against the abnormal gut colonization observed in gonadectomized pathogen-free male mice who were otherwise untreated, indicating a role of sex hormones in determining the composition of the gut microbiome (Org et al., 2016). Furthermore, genetic deletion of estrogen receptor β (ER β), the primary estrogen receptor in the colon (Langen et al., 2011), significantly alters gut microbiome composition in mice (Menon et al., 2013; Ma et al., 2022).

The gut microbiome plays a reciprocal role in modulating the production of sex hormones (Baker et al., 2017). The gut microbe Clostridium scindens has been shown to convert glucocorticoids into androgens in humans (Ridlon et al., 2013). Several different gut bacteria, including the genera Clostridium, Bacteroides, and Bifidobacterium, produce the enzyme β-glucuronidase (βGLU), which metabolizes endogenous and exogenous compounds including drugs, neurotransmitters, and hormones (Kwa et al., 2016; Gao et al., 2022). Specifically, β GLU is important for converting estrogen into its active form at which point it can induce its physiological effects (Hu et al., 2023). Post-menopausal women exhibit alterations in the diversity of β GLU producing bacteria (Flores et al., 2012; Silva et al., 2022; Hu et al., 2023), although an increased abundance of the Ruminococcus genus is positively correlated with estrogen metabolites among this population (Fuhrman et al., 2014; Wu et al., 2023).

Opioid use affects the gut microbiome

Chronic opioid use disrupts gut homeostasis in humans (Acharya et al., 2017; Barengolts et al., 2018; Gicquelais et al., 2020; Cruz-Lebrón et al., 2021; Yan et al., 2023). However, human studies are often limited by small sample sizes, polydrug use, and differences in dietary patterns, thus making it difficult to draw mechanistic conclusions. Animal studies have been crucial in identifying links between opioid-induced microbiome disruptions and changes in drug response (Akbarali and Dewey, 2017; Meckel and Kiraly, 2019). Several studies report the depletion of the Lactobacillus and Bifidobacterium bacterial strains in opioidexposed rodents (Zhang et al., 2019; Abu et al., 2024; Muchhala et al., 2024). Opioid exposure is also associated with alterations in the abundance of Firmicutes and Bacteroidetes in the gut (Banerjee et al., 2016; Simpson et al., 2020; Zhang et al., 2021; Antoine et al., 2022; Blakeley-Ruiz et al., 2022; Ghosh et al., 2023; Truitt et al., 2023; Crawford et al., 2024; Muchhala et al., 2024). Opioid-induced gut dysbiosis is also reported in gestational and neonatal exposure models (Grecco et al., 2021; Abu et al., 2022; 2024; Antoine et al., 2022; Lyu et al., 2022), which may have important implications for neonatal opioid withdrawal syndrome symptoms (Sealschott et al., 2020; 2024). Lastly, the mechanism of opioid administration can also affect the composition of the gut microbiome. Intermittent opioid intake via injections is more disruptive to gut homeostasis than sustained administration through a slow-release subcutaneous pellet (Lee et al., 2018), likely due to the recurring periods of withdrawal that are associated with intermittent exposure. Furthermore, intermittent opioid treatment is more likely to induce neuroimmune activation,

Reference	Species	Drug	Method of drug exposure	Age during drug exposure	Opioid-induced bacterial phyla or genus alteration	Behavioral/ physiological alteration
Ren and Loftipour (2022b)	Sprague Dawley rats	Fentanyl	IVSA	Adult	↓ <i>Verrucomicrobia</i> in males ↓ <i>Akkermansia</i> in males ↑ <i>Prevotella</i> in females ↑ <i>Ruminococcus</i> in males	Gut diversity within females was correlated with progressive ratio schedules during fentanyl IVSA
Greenberg et al. (2024)	NIH heterogeneous stock rats	Heroin	IVSA	Adult	↑ <i>Verrucomicrobia</i> in females ↑ <i>Actinobacteria</i> in females ↑ <i>Spirochaetes</i> in males ↑ <i>Tenericutes</i> in males	Males and females did not differ in drug intake during heroin IVSA
Lyu et al. (2022)	CF1 mice	Oxycodone	Intraperitoneal injection (dams)	Gestational	[↑] Saccharibacteria in females [↑] Enterococcus spp. in females [↑] Clostridia in males and females [↑] Butyricimonas spp. in females [↑] Bacteroidetes in females [↑] Anaeroplasma spp. in females [↑] Coriobacteriaceae in males [↑] Roseburia spp. in males [↑] Sutterella spp. in males	Males and females did not differ in behavioral outcomes
Antoine et al. (2022)	C57BL/6 mice	Morphine	Subcutaneous injection	Neonatal	↓ <i>Verrucomicrobia</i> in females ↓ <i>Bacteroidetes</i> in females ↓ <i>Actinobacteria</i> in females ↑ <i>Firmicutes</i> in females	
Ren and Loftipour (2022a)	Sprague Dawley rats	Fentanyl	IVSA	Adult	<i>↑Bacteroidetes</i> in antibiotic- treated males Females not analyzed	Antibiotic treatment enhanced fentanyl self-administration in males, but not females, at the lowest fixed ratio schedule
Ghosh et al. (2023)	C57BL/6 mice	Morphine	Subcutaneous pellet	Adult	↓Tenericutes ↓Actinobacteria ↓Bacteroidetes ↑Verrucomicrobia ↑Firmicutes Sex differences not analyzed	
Truitt et al. (2023)	C57BL/6 mice	Morphine	Subcutaneous pellet or intraperitoneal injection	Adult	↓ <i>Actinobacteria</i> ↓ <i>Firmicutes</i> ↑ <i>Verrucomicrobia</i> Sex differences not analyzed	Morphine-treated males and females did not differ in somatic withdrawal symptoms. Microbiome depletion prevented development of morphine withdrawal symptoms
Grecco et al. (2021)	C57BL/6 mice	Oxycodone/ Methadone	Subcutaneous injections (dams)	Gestational	↑Saccharimonadaceae ↑Peptococcaceae ↑Rikenellaceae Sex differences not analyzed	
Abu et al. (2022)	C57BL/6 mice	Hydromorphone	Intraperitoneal injection (dams)	Gestational	<i>↑Firmicutes</i> <i>↑Bacteoidetes</i> <i>↑Actinobacteria</i> Sex differences not analyzed	

TABLE 1 Opioid-induced microbiome alterations in studies using males and females. IVSA = intravenous self-administration.

hyperalgesia, and enhanced dopamine signaling in the nucleus accumbens (Lee et al., 2018; Lefevre et al., 2020).

Opioid-exposed animals supplemented with SCFAs exhibit reduced analgesic tolerance (Muchhala et al., 2024) and conditioned place preference (Hofford et al., 2021) compared to non-treated animals. SCFAs have also been shown to mediate the reversal of opioid-induced hyperalgesia (Jessup et al., 2023; Crawford et al., 2024). Microbiome depletion via antibiotic treatment attenuates withdrawal severity (Thomaz et al., 2021; Truitt et al., 2023) and reduces neuronal activation in brain regions implicated in opioid withdrawal (Simpson et al., 2020), suggesting that gut microbiota mediate the development of dependence. Antibiotic treatment has also been shown to attenuate opioid tolerance (Kang et al., 2017; Zhang et al., 2019) and drug-seeking behavior in the CPP (Hofford et al., 2021). However, in a separate study, antibiotic treatment was found to increase fentanyl intake during intravenous self-administration (IVSA), and this was eliminated by SCFA supplementation (Hofford et al., 2024). Thus, the relationship between the gut microbiome and opioid-induced behavior is complex, where increased or decreased microbial diversity could be beneficial depending on the circumstances.

Conclusions and future implications

There is compelling evidence indicating that both sex hormones and opioids modulate the composition and activity of the gut microbiome. Importantly, opioids suppress the hypothalamicpituitary-gonadal axis, which can lead to dysregulated endocrine functioning (Brennan, 2013; Marudhai et al., 2020; Wehbeh and Dobs, 2020). Chronic opioid use reduces the synthesis of testosterone in men (Rubinstein et al., 2013; Bawor et al., 2015) and estradiol and progesterone in women (Daniell, 2008). Furthermore, women who use opioids long-term are more likely to experience menstrual cycle abnormalities compared to short-term users (Daniell, 2008; Richardson et al., 2018). Thus, the effects of chronic opioid exposure on sex hormone regulation could in turn influence microbiome functioning in a sex-dependent manner.

Unfortunately, the majority of preclinical studies examining the effects of opioids on gut microbiota are conducted only in male animals or are not statistically powered to investigate sex differences. Despite this, notable sex differences have arisen among the small sample of studies that have examined the interaction between sex and gut microbiota in the context of opioid exposure (Table 1). Early-life opioid exposure differentially alters the gut microbiome in males versus females when measured later in life (Antoine et al., 2022; Lyu et al., 2022). In adults, IVSA induces distinct gut microbiome alterations in males compared to females, though no differences in addictive-like behavior were observed (Ren and Lotfipour, 2022b; Greenberg et al., 2024). In a separate study, microbiome depletion enhanced motivation for fentanyl at low schedules of reinforcement in males, but not females (Ren and Lotfipour, 2022a). Some studies, while including both males and females, did not explicitly test for sex differences in gut microbiome composition (Simpson et al., 2020; Grecco et al., 2021; Ghosh et al., 2023; Truitt et al., 2023). Thus, further investigation into the role of sex in opioid-induced gut dysbiosis and associated neurobehavioral effects is highly warranted. Future research should prioritize testing both male and female subjects and be designed to robustly evaluate sex as a biological variable (Radke et al., 2021; Shansky and Murphy, 2021). This is not to imply that the gut microbiome is the only factor driving sex differences in opioid response. However, this area of research is a promising avenue for gaining greater insight into the mechanisms governing opioid response, in addition to improving health outcomes for people who use opioids.

As opioids are commonly prescribed for postoperative pain (Hah et al., 2017), preventive interventions could be vital in managing adverse responses to opioids, particularly in high-risk populations. Dietary interventions targeted toward the gut microbiome could potentially attenuate the negative side effects of chronic opioid use. In mice undergoing oxycodone IVSA, treatment with dietary omega-3 polyunsaturated fatty acids diminished drug-seeking behavior during extinction and reinstatement and reduced anxiety-like behavior (Hakimian et al., 2019). Probiotics are commonly used for treating and preventing gut-related disorders (Liu et al., 2018), and more recently have gained traction as beneficial supplements to

medications for certain psychiatric disorders (Forth et al., 2023). The utilization of adjuvant probiotic treatment with prescription opioids may reduce symptoms driven by gut dysbiosis. Indeed, a small randomized, double-blinded, placebo-controlled study found that probiotic supplementation reduced depression severity and metabolic dysfunction in patients undergoing methadone maintenance treatment (Molavi et al., 2022). However, additional studies with larger cohorts are needed to verify these findings.

Distinct gut microbial profiles have recently been identified in patients with Alzheimer's disease (Ances et al., 2023), food addiction (Dong et al., 2020), and epilepsy (Gong et al., 2020), highlighting a growing interest in utilizing gut microbiome biomarkers as a diagnostic tool for a range of conditions. Moreover, sex-specific gut microbiome biomarkers have been discovered for major depressive disorder (Chen et al., 2018). Further characterization of sex-specific opioid-induced gut microbiome alterations could lead to implementing personalized medicine approaches based on microbial predictors (Ghanbari and Sumner, 2018). Thus, increased consideration of sex differences in the microbiome and its relationship to opioid response has significant therapeutic implications.

Author contributions

CH: Writing-original draft, Writing-review and editing, Conceptualization. MM: Writing-review and editing. SR: Conceptualization, Supervision, Writing-original draft, Writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by internal funding from Williams College.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Abu, Y., Tao, J., Dutta, R., Yan, Y., Vitari, N., Kolli, U., et al. (2022). Brief hydromorphone exposure during pregnancy sufficient to induce maternal and neonatal microbial dysbiosis. *J. Neuroimmune Pharmacol.* 17, 367–375. doi:10.1007/s11481-021-10019-2

Abu, Y. F., Singh, S., Tao, J., Chupikova, I., Singh, P., Meng, J., et al. (2024). Opioidinduced dysbiosis of maternal gut microbiota during gestation alters offspring gut microbiota and pain sensitivity. *Gut Microbes* 16, 2292224. doi:10.1080/19490976.2023. 2292224

Acharya, C., Betrapally, N. S., Gillevet, P. M., Sterling, R. K., Akbarali, H., White, M. B., et al. (2017). Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. *Aliment. Pharmacol. Ther.* 45, 319–331. doi:10.1111/apt.13858

Ahmed, A., Khan, F., Ali, M., Haqnawaz, F., Hussain, A., and Azam, S. I. (2012). Effect of the menstrual cycle phase on post-operative pain perception and analgesic requirements. *Acta Anaesthesiol. Scand.* 56, 629–635. doi:10.1111/j.1399-6576.2012. 02661.x

Ajayi, A. F., and Akhigbe, R. E. (2020). Staging of the estrous cycle and induction of estrus in experimental rodents: an update. *Fertil. Res. Pr.* 6, 5. doi:10.1186/s40738-020-00074-3

Akbarali, H. I., and Dewey, W. L. (2017). The gut-brain interaction in opioid tolerance. *Curr. Opin. Pharmacol.* 37, 126–130. doi:10.1016/j.coph.2017.10.012

Al-Azzawi, F., and Palacios, S. (2009). Hormonal changes during menopause. *Maturitas* 63, 135-137. doi:10.1016/j.maturitas.2009.03.009

Algera, M. H., Olofsen, E., Moss, L., Dobbins, R. L., Niesters, M., Velzen, M. van, et al. (2021). Tolerance to opioid-induced respiratory depression in chronic high-dose opioid users: a model-based comparison with opioid-naïve individuals. *Clin. Pharmacol. Ther.* 109, 637–645. doi:10.1002/cpt.2027

Ances, B., Ferreiro, A. L., Choi, J., Ryou, J., Newcomer, E., Stark, S. L., et al. (2023). The gut microbiome as an early biomarker of preclinical Alzheimer disease. *Alzheimer's Dement.* 19. doi:10.1002/alz.078811

Angoa-Pérez, M., and Kuhn, D. M. (2021). Evidence for modulation of substance use disorders by the gut microbiome: hidden in plain sight. *Pharmacol. Rev.* 73, 571–596. doi:10.1124/pharmrev.120.000144

Antoine, D., Singh, P. K., Tao, J., and Roy, S. (2022). Neonatal morphine results in long-lasting alterations to the gut microbiome in adolescence and adulthood in a murine model. *Pharmaceutics* 14, 1879. doi:10.3390/pharmaceutics14091879

Arumugam, M., Raes, J., Pelletier, E., Paslier, D. L., Yamada, T., Mende, D. R., et al. (2011). Enterotypes of the human gut microbiome. *Nature* 473, 174–180. doi:10.1038/ nature09944

Aubrun, F., Salvi, N., Coriat, P., and Riou, B. (2005). Sex- and age-related differences in morphine requirements for postoperative pain relief. *Anesthesiology* 103, 156–160. doi:10.1097/00000542-200507000-00023

Averitt, D. L., Eidson, L. N., Doyle, H. H., and Murphy, A. Z. (2019). Neuronal and glial factors contributing to sex differences in opioid modulation of pain. *Neuropsychopharmacology* 44, 155–165. doi:10.1038/s41386-018-0127-4

Badal, V. D., Vaccariello, E. D., Murray, E. R., Yu, K. E., Knight, R., Jeste, D. V., et al. (2020). The gut microbiome, aging, and longevity: a systematic review. *Nutrients* 12, 3759. doi:10.3390/nu12123759

Baker, J. M., Al-Nakkash, L., and Herbst-Kralovetz, M. M. (2017). Estrogen-gut microbiome axis: physiological and clinical implications. *Maturitas* 103, 45–53. doi:10. 1016/j.maturitas.2017.06.025

Baker, L., and Ratka, A. (2002). Sex-specific differences in levels of morphine, morphine-3-glucuronide, and morphine antinociception in rats. *Pain* 95, 65–74. doi:10.1016/s0304-3959(01)00376-1

Banerjee, S., Sindberg, G., Wang, F., Meng, J., Sharma, U., Zhang, L., et al. (2016). Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. *Mucosal Immunol.* 9, 1418–1428. doi:10.1038/mi.2016.9

Barengolts, E., Green, S. J., Eisenberg, Y., Akbar, A., Reddivari, B., Layden, B. T., et al. (2018). Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease. *PLoS ONE* 13, e0194171. doi:10.1371/journal.pone.0194171

Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., et al. (2015). Testosterone suppression in opioid users: a systematic review and meta-analysis. *Drug Alcohol Depend.* 149, 1–9. doi:10.1016/j.drugalcdep.2015.01.038

Blakeley-Ruiz, J. A., McClintock, C. S., Shrestha, H. K., Poudel, S., Yang, Z. K., Giannone, R. J., et al. (2022). Morphine and high-fat diet differentially alter the gut microbiota composition and metabolic function in lean versus obese mice. *ISME Commun.* 2, 66. doi:10.1038/s43705-022-00131-6

Bodnar, R. J., and Kest, B. (2010). Sex differences in opioid analgesia, hyperalgesia, tolerance and withdrawal: central mechanisms of action and roles of gonadal hormones. *Horm. Behav.* 58, 72–81. doi:10.1016/j.yhbeh.2009.09.012

Brennan, M. J. (2013). The effect of opioid therapy on endocrine function. Am. J. Med. 126, S12–S18. doi:10.1016/j.amjmed.2012.12.001

Butelman, E. R., Huang, Y., Epstein, D. H., Shaham, Y., Goldstein, R. Z., Volkow, N. D., et al. (2023). Overdose mortality rates for opioids and stimulant drugs are substantially higher in men than in women: state-level analysis. *Neuropsychopharmacology* 48, 1639–1647. doi:10.1038/s41386-023-01601-8

Center for Disease Control (CDC) (2024). Multiple cause of death 1999-2022 on CDC WONDER online database. Available at: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates (Accessed June 25, 2024).

Cepeda, M. S., and Carr, D. B. (2003). Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. *Anesth. Analg.* 97, 1464–1468. doi:10.1213/01.ane.0000080153.36643.83

Chen, J., Zheng, P., Liu, Y., Zhong, X., Wang, H., Guo, Y., et al. (2018). Sex differences in gut microbiota in patients with major depressive disorder. *Neuropsychiatr. Dis. Treat.* 14, 647–655. doi:10.2147/ndt.s159322

Cho, S., Ning, M., Zhang, Y., Rubin, L. H., and Jeong, H. (2016). 17 β -Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor a. *Acta Pharm. Sin. B* 6, 504–509. doi:10.1016/j.apsb.2016.04.005

Craft, R. M. (2003). Sex differences in opioid analgesia: "from mouse to man.". Clin. J. Pain 19, 175–186. doi:10.1097/00002508-200305000-00005

Craft, R. M. (2008). Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids. *Exp. Clin. Psychopharmacol.* 16, 376–385. doi:10.1037/a0012931

Crawford, J., Liu, S., Tao, R., Kramer, P., Bender, S., and Tao, F. (2024). The ketogenic diet mitigates opioid-induced hyperalgesia by restoring short-chain fatty acids-producing bacteria in the gut. *Pain* 165, e106–e114. doi:10.1097/j.pain. 00000000003212

Cronin, M., Ventura, M., Fitzgerald, G. F., and Sinderen, D. van (2011). Progress in genomics, metabolism and biotechnology of bifdobacteria. *Int. J. Food Microbiol.* 149, 4–18. doi:10.1016/j.ijfoodmicro.2011.01.019

Cruz-Lebrón, A., Johnson, R., Mazahery, C., Troyer, Z., Joussef-Piña, S., Quiñones-Mateu, M. E., et al. (2021). Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity. *Gut Microbes* 13, 1946368. doi:10.1080/19490976.2021. 1946368

Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., et al. (2019). The microbiota-gut-brain Axis. *Physiol. Rev.* 99, 1877–2013. doi:10.1152/physrev.00018.2018

Daniell, H. W. (2008). Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. *J. Pain* 9, 28–36. doi:10. 1016/j.jpain.2007.08.005

Dong, T. S., Mayer, E. A., Osadchiy, V., Chang, C., Katzka, W., Lagishetty, V., et al. (2020). A distinct brain-gut-microbiome profile exists for females with obesity and food addiction. *Obesity* 28, 1477–1486. doi:10.1002/oby.22870

Doyle, H. H., and Murphy, A. Z. (2018). Sex-dependent influences of morphine and its metabolites on pain sensitivity in the rat. *Physiol. Behav.* 187, 32–41. doi:10.1016/j. physbeh.2017.11.030

Emery, M. A., and Akil, H. (2020). Endogenous opioids at the intersection of opioid addiction, pain, and depression: the search for a precision medicine approach. *Annu. Rev. Neurosci.* 43, 355–374. doi:10.1146/annurev-neuro-110719-095912

Fillingim, R. B., and Ness, T. J. (2000). Sex-related hormonal influences on pain and analgesic responses. *Neurosci. Biobehav. Rev.* 24, 485–501. doi:10.1016/s0149-7634(00)00017-8

Fillingim, R. B., Ness, T. J., Glover, T. L., Campbell, C. M., Hastie, B. A., Price, D. D., et al. (2005). Morphine responses and experimental pain: sex differences in side effects and cardiovascular responses but not analgesia. J. Pain 6, 116–124. doi:10.1016/j.jpain. 2004.11.005

Flores, R., Shi, J., Fuhrman, B., Xu, X., Veenstra, T. D., Gail, M. H., et al. (2012). Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. *J. Transl. Med.* 10, 253. doi:10.1186/1479-5876-10-253

Forth, E., Buehner, B., Storer, A., Sgarbossa, C., Milev, R., and Meyyappan, A. C. (2023). Systematic review of probiotics as an adjuvant treatment for psychiatric disorders. *Front. Behav. Neurosci.* 17, 1111349. doi:10.3389/fnbeh.2023.1111349

Fuhrman, B. J., Feigelson, H. S., Flores, R., Gail, M. H., Xu, X., Ravel, J., et al. (2014). Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. *J. Clin. Endocrinol. Metab.* 99, 4632–4640. doi:10.1210/jc. 2014-2222

Fulenwider, H. D., Nennig, S. E., Hafeez, H., Price, M. E., Baruffaldi, F., Pravetoni, M., et al. (2020). Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats. *Addict. Biol.* 25, e12822. doi:10.1111/adb.12822

Fullerton, E. F., Doyle, H. H., and Murphy, A. Z. (2018). Impact of sex on pain and opioid analgesia: a review. *Curr. Opin. Behav. Sci.* 23, 183–190. doi:10.1016/j.cobeha. 2018.08.001 Gao, S., Sun, R., Singh, R., So, S. Y., Chan, C. T. Y., Savidge, T., et al. (2022). The role of gut microbial β -glucuronidase in drug disposition and development. *Drug Discov. Today* 27, 103316. doi:10.1016/j.drudis.2022.07.001

Ghanbari, R., and Sumner, S. (2018). Using metabolomics to investigate biomarkers of drug addiction. *Trends Mol. Med.* 24, 197–205. doi:10.1016/j.molmed.2017.12.005

Ghosh, N., Kesh, K., Singh, P. K., Sharma, U., Chupikova, I., Ramakrishnan, S., et al. (2023). Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signalling which is attenuated by proton pump inhibition. *Br. J. Pharmacol.* 180, 1582–1596. doi:10.1111/bph.16025

Gicquelais, R. E., Bohnert, A. S. B., Thomas, L., and Foxman, B. (2020). Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. *Sci. Rep.* 10, 19471. doi:10.1038/s41598-020-76570-9

Goldman, J. M., Murr, A. S., and Cooper, R. L. (2007). The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. *Birth Defects Res. Part B Dev. Reprod. Toxicol.* 80, 84–97. doi:10.1002/bdrb.20106

Gong, X., Liu, X., Chen, C., Lin, J., Li, A., Guo, K., et al. (2020). Alteration of gut microbiota in patients with epilepsy and the potential index as a biomarker. *Front. Microbiol.* 11, 517797. doi:10.3389/fmicb.2020.517797

Grecco, G. G., Gao, Y., Gao, H., Liu, Y., and Atwood, B. K. (2021). Prenatal opioid administration induces shared alterations to the maternal and offspring gut microbiome: a preliminary analysis. *Drug Alcohol Depend.* 227, 108914. doi:10.1016/ j.drugalcdep.2021.108914

Greenberg, J. M., Winters, A. D., Zagorac, B., Kracht, D. J., Francescutti, D. M., Cannella, N., et al. (2024). Long access heroin self-administration significantly alters gut microbiome composition and structure. *Front. Psychiatry* 15, 1369783. doi:10.3389/ fpsyt.2024.1369783

Gregori, S. D., Gregori, M. D., Ranzani, G. N., Allegri, M., Minella, C., and Regazzi, M. (2012). Morphine metabolism, transport and brain disposition. *Metab. Brain Dis.* 27, 1–5. doi:10.1007/s11011-011-9274-6

Hah, J. M., Bateman, B. T., Ratliff, J., Curtin, C., and Sun, E. (2017). Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. *Anesth. Analg.* 125, 1733–1740. doi:10.1213/ane.00000000002458

Hakimian, J. K., Dong, T. S., Barahona, J. A., Lagishetty, V., Tiwari, S., Azani, D., et al. (2019). Dietary supplementation with omega-3 polyunsaturated fatty acids reduces opioid-seeking behaviors and alters the gut microbiome. *Nutrients* 11, 1900. doi:10. 3390/nu11081900

Hall, A. B., Tolonen, A. C., and Xavier, R. J. (2017). Human genetic variation and the gut microbiome in disease. *Nat. Rev. Genet.* 18, 690–699. doi:10.1038/nrg.2017.63

Hantsoo, L., and Zemel, B. S. (2021). Stress gets into the belly: early life stress and the gut microbiome. *Behav. Brain Res.* 414, 113474. doi:10.1016/j.bbr.2021.113474

Harte-Hargrove, L. C., Varga-Wesson, A., Duffy, A. M., Milner, T. A., and Scharfman, H. E. (2015). Opioid receptor-dependent sex differences in synaptic plasticity in the hippocampal mossy fiber pathway of the adult rat. *J. Neurosci.* 35, 1723–1738. doi:10. 1523/jneurosci.0820-14.2015

Higgins, C., Smith, B. H., and Matthews, K. (2019). Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. *Br. J. Anaesth.* 122, e114–e126. doi:10.1016/j.bja.2018.09.019

Hofford, R. S., Meckel, K. R., Wiser, E. J., Wang, W., Sens, J. P., Kim, M., et al. (2024). Microbiome depletion increases fentanyl self-administration and alters the striatal proteome through short-chain fatty acids. *eNeuro* 11, e0388. doi:10.1523/eneuro.0388-23.2023

Hofford, R. S., Mervosh, N. L., Euston, T. J., Meckel, K. R., Orr, A. T., and Kiraly, D. D. (2021). Alterations in microbiome composition and metabolic byproducts drive behavioral and transcriptional responses to morphine. *Neuropsychopharmacology* 46, 2062–2072. doi:10.1038/s41386-021-01043-0

Hu, S., Ding, Q., Zhang, W., Kang, M., Ma, J., and Zhao, L. (2023). Gut microbial betaglucuronidase: a vital regulator in female estrogen metabolism. *Gut Microbes* 15, 2236749. doi:10.1080/19490976.2023.2236749

Jessup, D., Woods, K., Thakker, S., Damaj, M. I., and Akbarali, H. I. (2023). Shortchain fatty acid, butyrate prevents morphine-and paclitaxel-induced nociceptive hypersensitivity. *Sci. Rep.* 13, 17805. doi:10.1038/s41598-023-44857-2

Ji, Y., Murphy, A. Z., and Traub, R. J. (2007). Estrogen modulation of morphine analgesia of visceral pain in female rats is supraspinally and peripherally mediated. *J. Pain* 8, 494–502. doi:10.1016/j.jpain.2007.01.006

Joyce, K. M., Good, K. P., Tibbo, P., Brown, J., and Stewart, S. H. (2021). Addictive behaviors across the menstrual cycle: a systematic review. *Arch. Women's Ment. Heal.* 24, 529–542. doi:10.1007/s00737-020-01094-0

Kang, M., Mischel, R. A., Bhave, S., Komla, E., Cho, A., Huang, C., et al. (2017). The effect of gut microbiome on tolerance to morphine mediated antinociception in mice. *Sci. Rep.* 7, 42658. doi:10.1038/srep42658

Karami, M., and Zarrindast, M. R. (2008). Morphine sex-dependently induced place conditioning in adult Wistar rats. *Eur. J. Pharmacol.* 582, 78–87. doi:10.1016/j.ejphar. 2007.12.010

Kim N. (2022). Sex/gender-specific medicine in the gastrointestinal diseases (Singapore: Springer).

Knoop, K. A., Holtz, L. R., and Newberry, R. D. (2018). Inherited nongenetic influences on the gut microbiome and immune system. *Birth Defects Res.* 110, 1494–1503. doi:10.1002/bdr2.1436

Kurz, A., and Sessler, D. I. (2003). Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. *Drugs* 63, 649–671. doi:10.2165/00003495-200363070-00003

Kwa, M., Plottel, C. S., Blaser, M. J., and Adams, S. (2016). The intestinal microbiome and estrogen receptor–positive female breast cancer. *J. Natl. Cancer Inst.* 108, djw029. doi:10.1093/jnci/djw029

Lacy, R. T., Austin, B. P., and Strickland, J. C. (2020). The influence of sex and estrous cyclicity on cocaine and remifentanil demand in rats. *Addict. Biol.* 25, e12716. doi:10. 1111/adb.12716

Lacy, R. T., Strickland, J. C., Feinstein, M. A., Robinson, A. M., and Smith, M. A. (2016). The effects of sex, estrous cycle, and social contact on cocaine and heroin self-administration in rats. *Psychopharmacology* 233, 3201–3210. doi:10.1007/s00213-016-4368-9

Langen, M. L., Hotte, N., Dieleman, L. A., Albert, E., Mulder, C., and Madsen, K. L. (2011). Estrogen receptor- β signaling modulates epithelial barrier function. *Am. J. Physiol.-Gastrointest. Liver Physiol.* 300, G621–G626. doi:10.1152/ajpgi.00274.2010

Lee, K., Vuong, H. E., Nusbaum, D. J., Hsiao, E. Y., Evans, C. J., and Taylor, A. M. W. (2018). The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence. *Neuropsychopharmacology* 43, 2606–2614. doi:10.1038/s41386-018-0211-9

Lefevre, E. M., Pisansky, M. T., Toddes, C., Baruffaldi, F., Pravetoni, M., Tian, L., et al. (2020). Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system. *Neuropsychopharmacology* 45, 1781–1792. doi:10.1038/s41386-020-0643-x

LeResche, L., Saunders, K., Dublin, S., Thielke, S., Merrill, J. O., Shortreed, S. M., et al. (2015). Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain. *J. Women's Heal.* 24, 629–635. doi:10.1089/jwh.2015. 5222

Li, C., Peng, K., Xiao, S., Long, Y., and Yu, Q. (2023). The role of Lactobacillus in inflammatory bowel disease: from actualities to prospects. *Cell Death Discov.* 9, 361. doi:10.1038/s41420-023-01666-w

Liu, Y., Tran, D. Q., and Rhoads, J. M. (2018). Probiotics in disease prevention and treatment. J. Clin. Pharmacol. 58, S164–S179. doi:10.1002/jcph.1121

Lyu, Z., Schmidt, R. R., Martin, R. E., Green, M. T., Kinkade, J. A., Mao, J., et al. (2022). Long-term effects of developmental exposure to oxycodone on gut microbiota and relationship to adult behaviors and metabolism. *mSystems* 7, e0033622. doi:10.1128/ msystems.00336-22

Ma, Y., Liu, T., Li, X., Kong, A., Xiao, R., Xie, R., et al. (2022). Estrogen receptor β deficiency impairs gut microbiota: a possible mechanism of IBD-induced anxiety-like behavior. *Microbiome* 10, 160. doi:10.1186/s40168-022-01356-2

Marudhai, S., Patel, M., Subas, S. V., Ghani, M. R., Busa, V., Dardeir, A., et al. (2020). Long-term opioids linked to hypogonadism and the role of testosterone supplementation therapy. *Cureus* 12, e10813. doi:10.7759/cureus.10813

Meckel, K. R., and Kiraly, D. D. (2019). A potential role for the gut microbiome in substance use disorders. *Psychopharmacology* 236, 1513–1530. doi:10.1007/s00213-019-05232-0

Menon, R., Watson, S. E., Thomas, L. N., Allred, C. D., Dabney, A., Azcarate-Peril, M. A., et al. (2013). Diet complexity and estrogen receptor β status affect the composition of the murine intestinal microbiota. *Appl. Environ. Microbiol.* 79, 5763–5773. doi:10.1128/aem.01182-13

Miniksar, Ö. H., Onat, T., Gocmen, A. Y., and Honca, M. (2023). Serum levels of muopioid receptor according to menstrual cycle phases are associated with postoperative pain and opioid consumption in laparoscopic gynecological surgeries: a prospective observational study. Ir. J. Méd. Sci. (1971) 192, 1847–1854. doi:10.1007/s11845-022-03146-z

Mirbaha, H., Tabaeizadeh, M., Shaterian-Mohammadi, H., Tahsili-Fahadan, P., and Dehpour, A. R. (2009). Estrogen pretreatment modulates morphine-induced conditioned place preference in ovariectomized mice. *Pharmacol. Biochem. Behav.* 92, 399–403. doi:10.1016/j.pbb.2009.01.009

Molavi, N., Rasouli-Azad, M., Mirzaei, H., Matini, A. H., Banafshe, H. R., Valiollahzadeh, M., et al. (2022). The effects of probiotic supplementation on opioid-related disorder in patients under methadone maintenance treatment programs. *Int. J. Clin. P. R.* 2022, 1206914. doi:10.1155/2022/1206914

Muchhala, K. H., Kallurkar, P. S., Kang, M., Koseli, E., Poklis, J. L., Xu, Q., et al. (2024). The role of morphine- and fentanyl-induced impairment of intestinal epithelial antibacterial activity in dysbiosis and its impact on the microbiota-gut-brain axis. *FASEB J.* 38, e23603. doi:10.1096/fj.202301590rr

O'Callaghan, A., and Sinderen, D. van (2016). Bifidobacteria and their role as members of the human gut microbiota. *Front. Microbiol.* 7, 925. doi:10.3389/fmicb. 2016.00925

Org, E., Mehrabian, M., Parks, B. W., Shipkova, P., Liu, X., Drake, T. A., et al. (2016). Sex differences and hormonal effects on gut microbiota composition in mice. *Gut Microbes* 7, 313–322. doi:10.1080/19490976.2016.1203502 Pergolizzi, J. V., Raffa, R. B., and Rosenblatt, M. H. (2020). Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. *J. Clin. Pharm. Ther.* 45, 892–903. doi:10.1111/jcpt.13114

Phillips, A. G., McGovern, D. J., Lee, S., Ro, K., Huynh, D. T., Elvig, S. K., et al. (2020). Oral prescription opioid-seeking behavior in male and female mice. *Addict. Biol.* 25, e12828. doi:10.1111/adb.12828

Radke, A. K., Sneddon, E. A., and Monroe, S. C. (2021). Studying sex differences in rodent models of addictive behavior. *Curr. Protoc.* 1, e119. doi:10.1002/cpz1.119

Razavi, A. C., Potts, K. S., Kelly, T. N., and Bazzano, L. A. (2019). Sex, gut microbiome, and cardiovascular disease risk. *Biol. Sex. Differ.* 10, 29. doi:10.1186/s13293-019-0240-z

Reed, B. G., and Carr, B. R. (2015). "The normal menstrual cycle and the control of ovulation" in Endotext. Editors K. R. Feingold, B. Anawalt, M. R. Blackman, A. Boyce, G. Chrousos, and E. Corpas (South Dartmouth (MA): MDText.com, Inc.; 2000).

Reid, G. (1999). The scientific basis for probiotic strains of Lactobacillus. Appl. Environ. Microbiol. 65, 3763-3766. doi:10.1128/AEM.65.9.3763-3766.1999

Ren, M., and Lotfipour, S. (2022a). Antibiotic knockdown of gut bacteria sexdependently enhances intravenous fentanyl self-administration in adult sprague dawley rats. *Int. J. Mol. Sci.* 24, 409. doi:10.3390/ijms24010409

Ren, M., and Lotfipour, S. (2022b). Dose- and sex-dependent bidirectional relationship between intravenous fentanyl self-administration and gut microbiota. *Microorganisms* 10, 1127. doi:10.3390/microorganisms10061127

Reuben, D. B., Alvanzo, A. A. H., Ashikaga, T., Bogat, G. A., Callahan, C. M., Ruffing, V., et al. (2015). National institutes of health pathways to prevention workshop: the role of opioids in the treatment of chronic pain. *Ann. Intern. Med.* 162, 295–300. doi:10.7326/m14-2775

Ribeiro-Dasilva, M. C., Shinal, R. M., Glover, T., Williams, R. S., Staud, R., Riley, J. L., et al. (2011). Evaluation of menstrual cycle effects on morphine and pentazocine analgesia. *Pain* 152, 614–622. doi:10.1016/j.pain.2010.11.033

Richardson, E., Bedson, J., Chen, Y., Lacey, R., and Dunn, K. M. (2018). Increased risk of reproductive dysfunction in women prescribed long-term opioids for musculoskeletal pain: a matched cohort study in the Clinical Practice Research Datalink. *Eur. J. Pain* 22, 1701–1708. doi:10.1002/ejp.1256

Ridlon, J. M., Ikegawa, S., Alves, J. M. P., Zhou, B., Kobayashi, A., Iida, T., et al. (2013). Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. *J. Lipid Res.* 54, 2437–2449. doi:10.1194/jlr.m038869

Rizzetto, L., Fava, F., Tuohy, K. M., and Selmi, C. (2018). Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. *J. Autoimmun.* 92, 12–34. doi:10.1016/j.jaut.2018.05.008

Roth, M. E., Casimir, A. G., and Carroll, M. E. (2002). Influence of estrogen in the acquisition of intravenously self-administered heroin in female rats. *Pharmacol. Biochem. Behav.* 72, 313–318. doi:10.1016/s0091-3057(01)00777-8

Rubinstein, A. L., Carpenter, D. M., and Minkoff, J. R. (2013). Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. *Clin. J. Pain* 29, 840–845. doi:10.1097/ajp.0b013e31827c7b5d

Rueda-Ruzafa, L., Cruz, F., Cardona, D., Hone, A. J., Molina-Torres, G., Sánchez-Labraca, N., et al. (2020). Opioid system influences gut-brain axis: dysbiosis and related alterations. *Pharmacol. Res.* 159, 104928. doi:10.1016/j.phrs.2020.104928

Santos-Marcos, J. A., Rangel-Zuñiga, O. A., Jimenez-Lucena, R., Quintana-Navarro, G. M., Garcia-Carpintero, S., Malagon, M. M., et al. (2018). Influence of gender and menopausal status on gut microbiota. *Maturitas* 116, 43–53. doi:10.1016/j.maturitas. 2018.07.008

Schepper, H. U. D., Cremonini, F., Park, M.-I., and Camilleri, M. (2004). Opioids and the gut: pharmacology and current clinical experience. *Neurogastroenterol. Motil.* 16, 383–394. doi:10.1111/j.1365-2982.2004.00513.x

Sealschott, S., Pickler, R., Fortney, C., Bailey, M., and Loman, B. (2024). Gut microbiota and symptom expression and severity in neonatal abstinence syndrome. *Biol. Res. Nurs.* 26, 460–468. doi:10.1177/10998004241242102

Sealschott, S. D., Pickler, R. H., Fortney, C. A., and Bailey, M. T. (2020). Integrative review of gut microbiota and expression of symptoms associated with neonatal abstinence syndrome. *Nurs. Res.* 69, S66–S78. doi:10.1097/nnr.000000000000452

Sener, E. B., Kocamanoglu, S., Cetinkaya, M. B., Ustun, E., Bildik, E., and Tur, A. (2005). Effects of menstrual cycle on postoperative analgesic requirements, agitation, incidence of nausea and vomiting after gynecological laparoscopy. *Gynecol. Obstet. Investig.* 59, 49–53. doi:10.1159/000081222

Shansky, R. M., and Murphy, A. Z. (2021). Considering sex as a biological variable will require a global shift in science culture. *Nat. Neurosci.* 24, 457–464. doi:10.1038/s41593-021-00806-8

Sharp, J. L., Ethridge, S. B., Ballard, S. L., Potter, K. M., Schmidt, K. T., and Smith, M. A. (2021). The effects of chronic estradiol treatment on opioid self-administration in intact female rats. *Drug Alcohol Depend*. 225, 108816. doi:10.1016/j.drugalcdep.2021. 108816

Shin, J.-H., Park, Y.-H., Sim, M., Kim, S.-A., Joung, H., and Shin, D.-M. (2019). Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. *Res. Microbiol.* 170, 192–201. doi:10.1016/j.resmic.2019.03.003

Shobeiri, P., Kalantari, A., Teixeira, A. L., and Rezaei, N. (2022). Shedding light on biological sex differences and microbiota–gut–brain axis: a comprehensive review of its roles in neuropsychiatric disorders. *Biol. Sex. Differ.* 13, 12. doi:10.1186/s13293-022-00422-6

Silva, T. C. A. da, Gonçalves, J. A., dos, S., Souza, L. A. C. e., Lima, A. A., and Guerra-Sá, R. (2022). The correlation of the fecal microbiome with the biochemical profile during menopause: a Brazilian cohort study. *BMC Women's Heal* 22, 499. doi:10.1186/ s12905-022-02063-8

Silva, Y. P., Bernardi, A., and Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Front. Endocrinol.* 11, 25. doi:10. 3389/fendo.2020.00025

Simpson, S., Kimbrough, A., Boomhower, B., McLellan, R., Hughes, M., Shankar, K., et al. (2020). Depletion of the microbiome alters the recruitment of neuronal ensembles of oxycodone intoxication and withdrawal. *eNeuro* 7, e0312. doi:10.1523/eneuro.0312-19.2020

Sinha, T., Vila, A. V., Garmaeva, S., Jankipersadsing, S. A., Imhann, F., Collij, V., et al. (2019). Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles. *Gut Microbes* 10, 358–366. doi:10.1080/19490976.2018.1528822

Smith, M. A., Ethridge, S. B., Pearson, T., Zhang, H., Marcus, M. M., Ballard, S. L., et al. (2021). Modulation of heroin intake by ovarian hormones in gonadectomized and intact female rats. *Psychopharmacology* 238, 969–978. doi:10.1007/s00213-020-05743-1

Stoffel, E. C., Ulibarri, C. M., and Craft, R. M. (2003). Gonadal steroid hormone modulation of nociception, morphine antinociception and reproductive indices in male and female rats. *Pain* 103, 285–302. doi:10.1016/s0304-3959(02)00457-8

Stojanov, S., Berlec, A., and Štrukelj, B. (2020). The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. *Microorganisms* 8, 1715. doi:10.3390/microorganisms8111715

Sun, E. C., Darnall, B., Baker, L. C., and Mackey, S. (2016). Incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. *JAMA Intern. Med.* 176, 1286–1293. doi:10.1001/jamainternmed.2016.3298

Terner, J. M., Barrett, A. C., Grossell, E., and Picker, M. J. (2002). Influence of gonadectomy on the antinociceptive effects of opioids in male and female rats. *Psychopharmacology* 163, 183–193. doi:10.1007/s00213-002-1143-x

Terner, J. M., Lomas, L. M., and Picker, M. J. (2005). Influence of estrous cycle and gonadal hormone depletion on nociception and opioid antinociception in female rats of four strains. *J. Pain* 6, 372–383. doi:10.1016/j.jpain.2005.01.354

Thomaz, A. C., Iyer, V., Woodward, T. J., and Hohmann, A. G. (2021). Fecal microbiota transplantation and antibiotic treatment attenuate naloxone-precipitated opioid withdrawal in morphine-dependent mice. *Exp. Neurol.* 343, 113787. doi:10.1016/j.expneurol.2021.113787

Towers, E. B., Williams, I. L., Qillawala, E. I., Rissman, E. F., and Lynch, W. J. (2022). Sex/Gender differences in the time-course for the development of substance use disorder: a focus on the telescoping effect. *Pharmacol. Rev.* 75, 217–249. doi:10. 1124/pharmrev.121.000361

Truitt, B., Venigalla, G., Singh, P., Singh, S., Tao, J., Chupikova, I., et al. (2023). The gut microbiome contributes to somatic morphine withdrawal behavior and implicates a TLR2 mediated mechanism. *Gut Microbes* 15, 2242610. doi:10.1080/19490976.2023. 2242610

Turroni, F., Ventura, M., Buttó, L. F., Duranti, S., O'Toole, P. W., Motherway, M. O., et al. (2014). Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. *Cell. Mol. Life Sci.* 71, 183–203. doi:10. 1007/s00018-013-1318-0

Vaishampayan, P. A., Kuehl, J. V., Froula, J. L., Morgan, J. L., Ochman, H., and Francino, M. P. (2010). Comparative metagenomics and population dynamics of the gut microbiota in mother and infant. *Genome Biol. Evol.* 2, 53–66. doi:10.1093/gbe/evp057

Vowles, K. E., McEntee, M. L., Julnes, P. S., Frohe, T., Ney, J. P., and Goes, D. N. (2015). Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain* 156, 569–576. doi:10.1097/01.j.pain.0000460357.01998.f1

Wang, F., and Roy, S. (2017). Gut homeostasis, microbial dysbiosis, and opioids. *Toxicol. Pathol.* 45, 150–156. doi:10.1177/0192623316679898

Wehbeh, L., and Dobs, A. S. (2020). Opioids and the hypothalamic-pituitary-gonadal (HPG) Axis. J. Clin. Endocrinol. Metab. 105, dgaa417. doi:10.1210/clinem/dgaa417

Wilson, N., Kariisa, M., Seth, P., Smith, H., and Davis, N. L. (2020). Drug and opioidinvolved overdose deaths — United States, 2017–2018. *Morb. Mortal. Wkly. Rep.* 69, 290–297. doi:10.15585/mmwr.mm6911a4

Wood, J. D., and Galligan, J. J. (2004). Function of opioids in the enteric nervous system. *Neurogastroenterol. Motil.* 16, 17–28. doi:10.1111/j.1743-3150.2004.00554.x

Wu, Z., Pfeiffer, R. M., Byrd, D. A., Wan, Y., Ansong, D., Clegg-Lamptey, J.-N., et al. (2023). Associations of circulating estrogens and estrogen metabolites with fecal and oral microbiome in postmenopausal women in the Ghana breast health study. *Microbiol. Spectr.* 11, e0157223. doi:10.1128/spectrum.01572-23

Xu, Q., Jin, L., Wang, L., Tang, Y., Wu, H., Chen, Q., et al. (2024). The role of gonadal hormones in regulating opioid antinociception. *Ann. Med.* 56, 2329259. doi:10.1080/07853890.2024.2329259

Yan, P., Ma, H., Tian, W., Liu, J., Yan, X., Ma, L., et al. (2023). Methadone maintenance treatment is more effective than compulsory detoxification in

addressing gut microbiota dysbiosis caused by heroin abuse. Front. Microbiol. 14, 1283276. doi:10.3389/fmicb.2023.1283276

Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., et al. (2012). Human gut microbiome viewed across age and geography. *Nature* 486, 222–227. doi:10.1038/nature11053

Yoon, K., and Kim, N. (2021). Roles of sex hormones and gender in the gut microbiota. J. Neurogastroenterol. Motil. 27, 314–325. doi:10.5056/jnm20208

Yurkovetskiy, L., Burrows, M., Khan, A. A., Graham, L., Volchkov, P., Becker, L., et al. (2013). Gender bias in autoimmunity is influenced by microbiota. *Immunity* 39, 400–412. doi:10.1016/j.immuni.2013.08.013

Zaky, A., Glastras, S. J., Wong, M. Y. W., Pollock, C. A., and Saad, S. (2021). The role of the gut microbiome in diabetes and obesity-related kidney disease. *Int. J. Mol. Sci.* 22, 9641. doi:10.3390/ijms22179641

Zhang, J., Deji, C., Fan, J., Chang, L., Miao, X., Xiao, Y., et al. (2021). Differential alteration in gut microbiome profiles during acquisition, extinction and reinstatement of morphine-induced CPP. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 104, 110058. doi:10.1016/j.pnpbp.2020.110058

Zhang, L., Meng, J., Ban, Y., Jalodia, R., Chupikova, I., Fernandez, I., et al. (2019). Morphine tolerance is attenuated in germfree mice and reversed by probiotics, implicating the role of gut microbiome. *Proc. Natl. Acad. Sci.* 116, 13523–13532. doi:10.1073/pnas.1901182116